Related Experiment Videos
The macrolides: erythromycin, clarithromycin, and azithromycin
1Division of Infectious Diseases and Internal Medicine, Mayo Clinic Jacksonville, Florida, USA.
Mayo Clinic Proceedings
|June 23, 1999
Summary
New macrolides like azithromycin and clarithromycin offer improved stability and broader spectrum against infections such as Mycobacterium avium complex (MAC). However, increasing macrolide resistance is a growing concern for future antimicrobial effectiveness.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Erythromycin has been a primary macrolide antibiotic, but newer agents offer distinct advantages.
- Azithromycin and clarithromycin represent advancements in macrolide antibiotic therapy.
Purpose of the Study:
- To compare the chemical stability, antimicrobial spectrum, pharmacokinetics, and clinical applications of azithromycin and clarithromycin versus erythromycin.
- To highlight the efficacy of azithromycin and clarithromycin in treating specific infections, including Mycobacterium avium complex (MAC) and atypical respiratory pathogens.
- To address the emerging issue of macrolide resistance and its potential impact on future treatment strategies.
Main Methods:
- Comparative analysis of chemical stability and antimicrobial spectrum.
- Pharmacokinetic profiling to assess dosing schedules and tissue penetration.
- Review of clinical data regarding efficacy in MAC prophylaxis and treatment, respiratory tract infections, skin/soft tissue infections, community-acquired pneumonia, and pelvic inflammatory diseases.
- Assessment of drug-drug interactions and pediatric tolerance.
Main Results:
- Azithromycin and clarithromycin exhibit enhanced chemical stability and broader antimicrobial activity compared to erythromycin, particularly against MAC, H. influenzae, and C. trachomatis.
- Both agents demonstrate excellent activity against atypical respiratory pathogens (C. pneumoniae, Mycoplasma) and Legionella species.
- Pharmacokinetics allow for shorter dosing schedules; both are effective for MAC prophylaxis in AIDS patients, with azithromycin preferred due to fewer interactions.
- Clarithromycin is crucial for treating active MAC disease; azithromycin offers advantages in pediatric compliance.
- Increasing macrolide resistance in S. pneumoniae, group A streptococci, and H. influenzae is a significant concern.
Conclusions:
- Azithromycin and clarithromycin are valuable macrolide antibiotics with improved profiles over erythromycin, offering effective treatment options for various infections.
- Their pharmacokinetic properties and efficacy in specific patient populations (e.g., AIDS, children) enhance therapeutic utility.
- The rising prevalence of macrolide resistance poses a threat to the long-term clinical effectiveness of this antibiotic class.